Italian austerity measures include generic price cuts

Home/Policies & Legislation | Posted 18/06/2010 post-comment0 Post your comment

The Italian government has joined many other European countries in introducing measures to slash public spending. Italy’s government has approved a Euros 24 billion austerity package aimed at reducing the national budget deficit – which last year was 5.3% of its gross domestic product – to within the euro-zone limit of 3% by 2012. Cuts aimed at generic medicines are also included amongst these measures.


Italy has a very small generics market, which can be attributed to the low cost of patented drugs in the country. In 2009, generic drug sales reached a value of Euros 1.14 billion, represented just 6% of the overall market by value. By 2014, it is expected to be worth Euros 2.63 billion and by 2019, generic medicine sales are expected to reach a value of Euros 3.25 billion.

According to the measures, to be implemented up to 31 December 2010, generic medicines in Italy will be faced with a 12.5% reduction in the retail price.

Additionally, from 2011, the AIFA (the Italian Medicines Agency) is to identify a maximum of four generic drugs to be reimbursed by the national health system for drugs whose patent has expired. The decision on which four generic drugs are chosen will most likely be influenced by cost, therefore encouraging competition within the generic medicines market in Italy and forcing medicine prices to decline.

Furthermore, aiming to make annual savings of at least Euros 600 million, AIFA is to review the pharmaceutical expenditure of the various territorial regions in Italy in order to provide ‘tools’ that will encourage prescription of cheaper generic drugs.

This focus on generic drugs puts the economic sustainability of Europe’s generics sector in danger, especially as the use of reference pricing systems could lead to price cuts on lower-value medicines being enforced in low volume markets.

(see also Spanish government introduces harsh generic price cuts and Austerity measures introduced in Portugal affect generics)

comment icon Comments (0)
Post your comment
Related content
PDUFA VI: FDA could promote generics competition
47 MD001813
Home/Policies & Legislation Posted 29/07/2022
House bill passes FDA funding fees but conflicts with Senate bill
User Fee V13H23
Home/Policies & Legislation Posted 15/07/2022
US Senate clarifies status of interchangeable biosimilar exclusivity
Interchangeability V18K30
Home/Policies & Legislation Posted 27/05/2022
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010